Real-world insights from comprehensive genomic profiling in patients with metastatic castration-resistant prostate cancer
CGP identified BRCA PVs, MSI-high, or TMB-high in 20% of patients with metastatic CRPC, supporting its value in guiding precision oncology. However, only some patients received matched therapy, supporting earlier CGP testing. Routine integration of CGP may facilitate precision oncology-guided treatment decision-making in this population.
Authors
- Tetsuya Urasaki (ORCID: https://orcid.org/0000-0002-2342-8726)
- Ichiro Yonese (ORCID: https://orcid.org/0009-0001-2607-1013)
- Sadakatsu Ikeda (ORCID: https://orcid.org/0000-0003-1629-7171)
- Noboru Numao (ORCID: https://orcid.org/0000-0003-4024-4248)
- YUTA SANO
- J. Yonese
- M. Ito
- F. Koga
- Y. Miura
- Yosuke Yasuda
- Yoh Matsuoka
- Yasuhisa Fujii
- Hajime Tanaka
- Yuki Nakamura
- Soichiro Yoshida
Institutions
- Tokyo Medical and Dental University (JP)
- Tokyo Metropolitan Komagome Hospital (JP)
- Saitama Cancer Center (JP)
- The Cancer Institute Hospital (JP)
- Japanese Foundation For Cancer Research (JP)
- The University of Tokyo (JP)
Publication Details
- Journal
- Japanese Journal of Clinical Oncology
- Published
- 2026-02-23
- DOI
- https://doi.org/10.1093/jjco/hyag039
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00